SUMO2 Antikörper

Produktnummer ABIN3026258

Dieses Maus Monoklonal-Antikörper erkennt spezifisch SUMO2 in IF, FACS und IHC (p). Er zeigt eine Reaktivität gegenüber Human und Ratte.

Kurzübersicht für SUMO2 Antikörper (ABIN3026258)

Target: SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Reaktivität: Human, Ratte

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SUMO2 Antikörper ist unkonjugiert

Applikation: Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: SUMO2-1199

Produktdetails anti-SUMO2 Antikörper

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant human protein was used as the immunogen for the SUMO-2 antibody.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the SUMO-2 antibody should be determined by the researcher.

1. Staining of formalin/paraffin tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the SUMO-2 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu SUMO2

Target: SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Andere Bezeichnung: SUMO-2

Hintergrund: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer s disease.

Pathways: Methionine Biosynthetic Process